» Articles » PMID: 3197980

Prostaglandin E2 is a Mediator of 5-hydroxytryptamine Induced Water and Electrolyte Secretion in the Human Jejunum

Overview
Journal Gut
Specialty Gastroenterology
Date 1988 Oct 1
PMID 3197980
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Studies in the rat jejunum in vivo have shown that 5-hydroxytryptamine (5-HT) causes secretion of fluid and luminal release of prostaglandin (PG) E2. These effects can be blocked by indomethacin and ketanserin, which suggests that PGE2 may be an important intermediate in the transduction mechanism leading to 5-HT induced fluid secretion. To test this hypothesis in man 'steady state' perfusions (9 ml/min) were done in eight healthy volunteers using the triple lumen technique. The proximal jejunum was perfused with Ringer's solution which contained 51Cr-EDTA as a non-absorbable marker. Before and after the administration of indomethacin (1.0 mg/kg iv) the effects of exogenous 5-HT (10 micrograms/kg/min iv) on jejunal net transport of fluid and electrolytes and jejunal flow rate (JFR) of PGE2 were measured in 15-min periods for 2 x 60 minutes after a 60 minute control period. 5-HT reversed fluid and electrolyte absorption into profuse secretion (p less than 0.01, Duncan's multiple range test) and significantly increased JFR of PGE2 (p less than 0.01). Indomethacin partly restored fluid and electrolyte absorption (p less than 0.01) and inhibited JFR of PGE2 (p less than 0.05). These results provide further evidence in favour of the theory that PGs are involved in 5-HT induced intestinal fluid secretion.

Citing Articles

FFA2 activation combined with ulcerogenic COX inhibition induces duodenal mucosal injury via the 5-HT pathway in rats.

Akiba Y, Maruta K, Narimatsu K, Said H, Kaji I, Kuri A Am J Physiol Gastrointest Liver Physiol. 2017; 313(2):G117-G128.

PMID: 28526687 PMC: 5582879. DOI: 10.1152/ajpgi.00041.2017.


Indomethacin therapy effective in a patient with depletion syndrome from secretory villous adenoma.

Kagan M, Schmidt K, Sangha G BMJ Case Rep. 2017; 2017.

PMID: 28188165 PMC: 5307283. DOI: 10.1136/bcr-2016-217211.


Effect of lipopolysaccharide on diarrhea and gastrointestinal transit in mice: roles of nitric oxide and prostaglandin E2.

Liang Y, Liu H, Chen S, Chen C, Chou L, Tsai L World J Gastroenterol. 2005; 11(3):357-61.

PMID: 15637744 PMC: 4205337. DOI: 10.3748/wjg.v11.i3.357.


Novel targets for the control of secretory diarrhoea.

Farthing M Gut. 2002; 50 Suppl 3:III15-8.

PMID: 11953327 PMC: 1867674. DOI: 10.1136/gut.50.suppl_3.iii15.


Intestinal epithelial function: the case for immunophysiological regulation. Implications for disease (2).

McKay D, Perdue M Dig Dis Sci. 1993; 38(9):1735-45.

PMID: 8359088 DOI: 10.1007/BF01303185.


References
1.
Cooper H, Levitan R, Fordtran J, INGELFINGER F . A method for studying absorption of water and solute from the human small intestine. Gastroenterology. 1966; 50(1):1-7. View

2.
Brunsson I, Sjoqvist A, Jodal M, Lundgren O . Mechanisms underlying the small intestinal fluid secretion caused by arachidonic acid, prostaglandin E1 and prostaglandin E2 in the rat in vivo. Acta Physiol Scand. 1987; 130(4):633-42. DOI: 10.1111/j.1748-1716.1987.tb08186.x. View

3.
Matuchansky C, BERNIER J . Effect of prostaglandin E 1 on glucose, water, and electrolyte absorption in the human jejunum. Gastroenterology. 1973; 64(6):1111-8. View

4.
Cummings J, Newman A, Billings J, Misiewicz J . Colonic and small intestinal response to intravenous prostaglandin F2 alpha and E2 in man. Gut. 1975; 16(1):42-6. PMC: 1410937. DOI: 10.1136/gut.16.1.42. View

5.
Donowitz M, Binder H . Jejunal fluid and electrolyte secretion in carcinoid syndrome. Am J Dig Dis. 1975; 20(12):1115-22. DOI: 10.1007/BF01070754. View